I liked the comparisons Vince subtly drew between BOT and the 2 companies he oversaw the sale of -
1. One of the main reasons was the unique platform that had been built to support reaching clientele and 2. A stand alone new drug in a highly commercial space.
Now that sounds like a Company I know of........
Ann: Botanix Commercial Day Webinar Presentation, page-72
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.010(2.82%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.3¢ | 34.5¢ | $582.2K | 1.679M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32454 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 210000 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |